赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Shigella Infections (Shigellosis) Overview 7
Therapeutics Development 8
Pipeline Products for Shigella Infections (Shigellosis) – Overview 8
Pipeline Products for Shigella Infections (Shigellosis) – Comparative Analysis 9
Shigella Infections (Shigellosis) – Therapeutics under Development by Companies 10
Shigella Infections (Shigellosis) – Therapeutics under Investigation by Universities/Institutes 11
Shigella Infections (Shigellosis) – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Shigella Infections (Shigellosis) – Products under Development by Companies 14
Shigella Infections (Shigellosis) – Products under Investigation by Universities/Institutes 15
Shigella Infections (Shigellosis) – Companies Involved in Therapeutics Development 16
Anacor Pharmaceuticals, Inc. 16
GlaxoSmithKline plc 17
GlycoVaxyn AG 18
Shigella Infections (Shigellosis) – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
1790GAHB Vaccine – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GVXNSD-133 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
INX-201 – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
KKL-35 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
shigella vaccine – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
shigella vaccine – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Shigella Vaccine – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
shigella vaccine 1 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
shigellosis [Shigella flexneri 2a] (whole cell) vaccine – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Shigetec – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule for Shigellosis – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Inhibit Rns and VirF for Bacterial Infections – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Shigella Infections (Shigellosis) – Recent Pipeline Updates 38
Shigella Infections (Shigellosis) – Dormant Projects 39
Shigella Infections (Shigellosis) – Discontinued Products 40
Shigella Infections (Shigellosis) – Product Development Milestones 41
Featured News & Press Releases 41
Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 41
Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 41
Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions 42
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 43
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 44
Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47